Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-12-31

Summary

This study aims to evaluate the value of Shexiang Baoxin Pill (MUSKARDIA) in patients with acute myocardial infarction (AMI) through a prospective, multicenter, pragmatic randomized controlled real-world study. It seeks to validate its efficacy in reducing cardiovascular event risk during the peri-PCI period, as well as its effects on cardiac function, quality of life , and relevant biomarkers. Through this research, we expect to provide higher-quality evidence for the application of SBP in AMI patients undergoing PCI, thereby further optimizing comprehensive treatment strategies for AMI.

• Phase: PHASE4

Details

• Lead Sponsor: Shanghai Hutchison Pharmaceuticals Limited
• Collaborators: Affiliated Hospital of Jiangsu University; Affiliated Hospital of Shandong University of Traditional Chinese Medicine; Ankang Central Hospital; Ansteel Group General Hospital; Anyang Area Hospital of Puyang City; Beijing Chao Yang Hospital; Beijing Electric Power Hospital; Beijing Friendship Hospital; Cangzhou Central Hospital; Changzhi Medical College; Chaohu Hospital of Anhui Medical University; Civil Aviation General Hospital; Dazhou First People's Hospital; First Affiliated Hospital of Fujian Medical University; First Affiliated Hospital of Nanyang Medical College; First Affiliated Hospital of Ningbo University; First People's Hospital of Chenzhou; General Hospital of Fuxin Mining Industry Group of Liaoning Health Industry Group; General Hospital of Ningxia Medical University; Guilin People's Hospital; Handan Central Hospital; Huai'an First People's Hospital; Huaibei Miners General Hospital; Huaihe Hospital of Henan University; Huang Shan People's Hospital; Huashan Hospital; Inner Mongolia Autonomous Region People's Hospital; Ji'an Central People's Hospital; Jiangxi Provincial People's Hopital; Jiaozuo Second People's Hospital; Jilin Province People's Hospital; Jingzhou Central Hospital; Jinhua Central Hospital; Jining First People's Hospital; Lanzhou University Second Hospital; LinFen People's Hospital; Linyi People's Hospital; Longhua Hospital; North China University of Science and Technology; Peking University People's Hospital; People's Hospital of Chongqing; People's Hospital of Quzhou; Qianfoshan Hospital; Renmin Hospital of Wuhan University; Rizhao People's Hospital; Second Affiliated Hospital of Soochow University; Second Affiliated Hospital, School of Medicine, Zhejiang University; Second Xiangya Hospital of Central South University; Shandong Provincial Hospital; Shanghai 10th People's Hospital; Shanghai 6th People's Hospital; Shanghai East Hospital; Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Zhongshan Hospital; Shanxi Cardiovascular Hospital; Shaoguan People's Hospital; Shijiazhuang People's Hospital; Shuguang Hospital of Shanghai University of Traditional Chinese Medicine; Sir Run Run Shaw Hospital; Taizhou Enze Medical Center Group; The Affiliated Hospital of Qingdao University; The Affiliated Hospital Of Southwest Medical University; The Central Hospital of Shaoyang; The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Guangdong Pharmaceutical University; The First Affiliated Hospital of Henan University of Science and Technology; The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of University of South China; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital with Nanjing Medical University; the First Hospital of Anhui University of Science and Technology; The First Hospital of Hebei Medical University; The First People's Hospital of Changde City; The First People's Hospital of Chu Zhou; The First People's Hospital of Lianyungang; The First People's Hospital of Nanning; The People' s Hospital of Jiangmen; The People's Hospital of Jizhou District, Tianjin; The People's Hospital of Langfang City; The Second Affiliated Hospital of Fujian Medical University; The Second Affiliated Hospital of Hainan Medical University; The second People's Hospital of Guiyang; The Southwest Hospital of Army Medical University; The Third Affiliated Hospital of Guangzhou Medical University; The Third Affiliated Hospital of Wenzhou Medical University; The Third People's Hospital of Chengdu; The Tirst People's Hospital of Mianyang; Tianjin Third Central Hospital; Tongling People's Hospital; Weifang People's Hospital; Weihai Municipal Hospital; Wuhan No.1 Hospital; Wuxi People's Hospital; Xiangya Hospital of Central South University; Xiangyang Central Hospital; Xingtai Central Hospital; Xuancheng people's hospital; Xuanwu Hospital, Beijing; Xuzhou New Health Hospital; Yan'an Hospital of Kunming City; Yangchun People's Hospital; Yueyang Central Hospital; Zhoukou Central Hospital; ZhuZhou Central Hospital
• Treatments: Adrenergic beta-Antagonists; Aspirin; Cholesterol; Diet; Educational Status; Exercise; shexiang baoxin